Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk ...

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a ...

50% LDL-C reduction from baseline and the new lower LDL-C target of < 55 mg/dL for those with, or at very hisk for, CVD Lerodalcibep reduced mean Apo B by 45% and median Lp(a) by 30-32% Lerodalcibep ...

The placebo-adjusted reductions were up to 85.8% using an intact Lp(a) assay and up to 70.0% using an apo(a) assay. Specifically, the reductions were 47.6% at 10 mg, 81.7% at 60 mg and 85.8% at 240 mg ...

Mulvalaplin works, Nicholls explained at the press briefing, by disrupting the bonding of apo(a) to apoB, which does not allow Lp(a) to form. The study examined 3 different doses, at 10 mg, 60 mg and ...

This particular genetic type of leukemia is present in approximately 10% of cases, and is difficult to treat, leading to high ...